Press

  • Successful feasibility studies drive new Novozymes-EpiVax agreement

    Posted on December 22, 2014 by Annie De Groot
    EpiVax Inc. enters license agreement with Novozymes Biopharma to advance pioneering treatment of autoimmune diseases Novozymes’ Veltis® albumin-based half-life extension platform will help move Tregitope treatment for autoimmune diseases closer to clinical development. Providence, RI. Monday December 22, 2014 EpiVax and Novozymes Biopharma today announced that they have entered a license agreement for the development of novel ...
    Read more
  • Antigen Specific Tolerance Induction at Immunogenicity Summit Nov 19 2014

    Posted on November 18, 2014 by Annie De Groot
    Why is antigen-specificity key for biologics?  Annie De Groot, MD, CEO and CSO of EpiVax will be speaking at the CHI Immunogenicity summit on this topic, November 19th at 3 PM. It’s well known that tolerance can be induced by powerful transplant drugs but combining those powerful agents with biologics would not be generally acceptable (certainly not ...
    Read more
  • The Story-Telling-Cloth – Or how we use Textiles as Social Media to improve Vaccine Uptake

    Posted on November 4, 2014 by Annie De Groot
    GAIA Vaccine Foundation’s Story-Telling Cloth receives “Grand Challenges Explorations Grant” Award For West African-Style “Social Media” Cervical Cancer Prevention Campaign Providence, Rhode Island, 04 November 2014. The Bill and Melinda Gates Foundation awarded $100,000 to GAIA Vaccine Foundation to test whether dissemination of a printed cloth that tells the story of HPV, coupled with a media campaign ...
    Read more
  • Chugai Licenses ISPRI and OptiMatrix Platform from EpiVax for De-Risking Biologics

    Posted on October 29, 2014 by Annie De Groot
    Providence, Rhode Island. October 30, 2014 Chugai Pharmaceutical Co. signed an agreement with Rhode Island-based biotechnology company, EpiVax, Inc., to incorporate EpiVax’s ISPRI immunogenicity screening and deimmunization technology into Chugai’s drug development toolbox. Chugai is widely regarded as one of the most cutting edge biopharmaceutical companies in Japan, Researchers at Chugai will be utilizing the cloud-based in ...
    Read more
  • And . . . Why **Don't** we have an Ebola Vaccine Yet?

    Posted on October 21, 2014 by Annie De Groot
    Ebola: It is better to Prevent than to Cure These days, every conversation starts with this question: Why don’t we have a vaccine against Ebola? Francis Collins, Director of the National Institutes of Health, gave the right answer in a recent interview: “Frankly, if ...
    Read more
  • Senator Whitehouse

    Senator Whitehouse, Homeland Security Headline Vaccine Renaissance Conference

    Posted on October 14, 2014 by Annie De Groot
    Senator Whitehouse (RI) addressed more than 100 experts in the field of vaccine development today at the 8th Vaccine Renaissance, an annual event organized by the University of Rhode Island’s Institute for Immunology and Informatics and supported by EpiVax. He stated that it was tragic that the Sequester achieved what it set out to do – to be a ...
    Read more
  • 8th Vaccine Renaissance October 13-16 2014

    Posted on October 8, 2014 by Annie De Groot
    Vaccine experts to gather in Providence as fight against deadly diseases carries on   Providence, R.I. – October 8, 2014 – As many African countries as well as the United States continue to grapple with the outbreak of Ebola and other deadly diseases, the University of Rhode Island is getting ready to play host to some of ...
    Read more
  • De Groot named one of 50 Top "Vaccine Influencers"

    Posted on September 8, 2014 by Annie De Groot
    For Immediate Release For Further Information: Media Spokesperson 401 272-2123 EpiVax,Inc. Info@EpiVax.com EpiVax CEO/CSO Annie De Groot MD named one of the 50 most influential people in Vaccines PROVIDENCE, R.I. – September 09, 2014 – EpiVax CEO and University of Rhode Island professor Annie De Groot M.D. has been named one of the most influential people in the vaccine industry by the national ...
    Read more
  • New Analysis of 99 Ebola Sequences Published August 29th

    Posted on August 30, 2014 by Annie De Groot
    Matt Ardito (EpiVax IMF team-member) did a quick analysis of the new Ebola sequences on Friday August 29th. He downloaded the newly published Ebolavirus GP proteins from GenBank. After loading the new sequences (from http://www.ncbi.nlm.nih.gov/bioproject/PRJNA257197) into IVAX, he selected the 16 original Ebola clusters that EpiVax immunoinformatician Guilhem Richard (IMF team-member) found in his ...
    Read more
  • Ebola – Extending our Hand to Help

    Posted on August 17, 2014 by Annie De Groot
    Ebola - Extending our Hand to Help
    Read more
  • New Immunogenicity Analysis Tool: CHOPPI

    Posted on July 8, 2014 by Anthony Marcello
    New Immunogenicity Analysis Tool Emerges from Dartmouth-EpiVax-URI Collaboration “In Silico” Host Cell Protein for Protein Therapeutics Providence, RI. Tuesday, July 8th, 2014 A Public-private partnership resulted in the development of a new web-based tool that will help manufacturers of protein-based therapeutics improve the safety of their manufacturing processes, avoiding problems that caused the FDA to suspend a ...
    Read more
  • CV4 Submission Deadline Extended!

    Posted on June 24, 2014 by Anthony Marcello
    We are pleased to announce an extension of the deadline to submit full-length papers to the 4th Computational Vaccinology Workshop. The deadline, originally July 1st will be extended to August 4th.  The deadline for poster abstracts is August 25th. Hopefully this extra time will allow you to polish your submissions to this exciting workshop. For more details ...
    Read more
  • NEWS: Vaccines are not associated with autism

    Posted on May 21, 2014 by Anthony Marcello
    Vaccines are not associated with autism: An evidence-based meta-analysis of case-control and cohort studies Luke E. Taylor, Amy L. Swerdfeger, Guy D. Eslick (Not an EpiVax publication) Highlights • Five cohort studies involving 1,256,407 children and five case-control studies involving 9920 children were included in this analysis. • There was no relationship between vaccination and autism (OR: 0.99; 95% CI: 0.92 to ...
    Read more
  • EpiVax Immunogenicity Seminar – September 17th 2014 at the Westin Tokyo

    Posted on May 12, 2014 by Anthony Marcello
    EpiVax will be in Tokyo Japan from September 14th-20th, 2014 hosting our semiannual immunogenicity seminar and meeting with collaborators. The Westin Immunogenicity Seminar is scheduled for September 17th, 2014. The purpose of this seminar is to bridge the gap between recent academic research on Tregs, Tregitopes and protein drug development (immunogenicity, deimmunization and tolerance induction). Links PDF Agenda Last year’s event ...
    Read more
  • De Groot to speak at ASCLS-CNE event

    Posted on April 24, 2014 by Anthony Marcello
    APRIL 24, 2014 EpiVax CEO/CSO, Dr. Annie De Groot MD, will be one of the featured speakers during next week’s 66th Annual Clinical Laboratory Science Convention. The event is scheduled for April 29 through May 1 at the Rhode Island Convention Center in Providence. Dr. De Groot will speak on Tuesday, April 29 during a workshop on ...
    Read more

Join our newsletter

We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content.  Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.

Click Here